JetBlue Launches New B/E Aerospace Seating Partnership

WELLINGTON, Fla.--(BUSINESS WIRE)--

B/E Aerospace (BEAV), the worlds leading manufacturer of aircraft cabin interior products and the worlds leading provider of aerospace fasteners, consumables and logistics services, today announced that JetBlue Airways is launching new B/E Aerospace economy Pinnacle seats for JetBlues core economy seating at a media event today in New York City. B/E Aerospace will retrofit approximately 70 JetBlue Airbus A320 aircraft and will outfit approximately 30 brand new Airbus A321s that will join the JetBlue fleet over the next few years with its Pinnacle seats. In addition, there are options to retrofit up to approximately 60 additional A320 aircraft.

The B/E Aerospace Pinnacle main cabin seating platform is the industrys lightest full-featured economy class seat. The Pinnacle seat provides JetBlue customers with superior ergonomic comfort, modern design features, and best-in-class technology while lowering the airlines cost of ownership due to lighter, more reliable equipment.

Amin J. Khoury, Founder, Chairman and Chief Executive Officer of B/E Aerospace stated, We are very pleased to partner with JetBlue, which is renowned for its customer experience, and to further enhance the airlines reputation of providing its customers with the unique JetBlue Experience by outfitting their aircraft with our very comfortable Pinnacle seats. Since its launch, the Pinnacle seating platform has captured awards to equip more than 2,000 new or existing aircraft. These awards are valued in excess of $1.2 billion and are for both narrow-body and wide-body aircraft. Todays event by JetBlue continues to show the strength of one of our most successful new product launches ever.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve risks and uncertainties. The Companys actual experience and results may differ materially from the experience and results anticipated in such statements. Factors that might cause such a difference include those discussed in the Companys filings with the Securities and Exchange Commission (SEC), which include its Proxy Statement, Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. For more information, see the section entitled "Forward-Looking Statements" contained in the Companys Annual Report on Form 10-K and in other filings. The forward-looking statements included in this news release are made only as of the date of this news release and, except as required by federal securities laws and rules and regulations of the SEC, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About B/E Aerospace, Inc.

B/E Aerospace is the worlds leading manufacturer of aircraft cabin interior products and the worlds leading provider of aerospace fasteners, consumables and logistics services. B/E Aerospace designs, develops and manufactures a broad range of products for both commercial aircraft and business jets. B/E Aerospace manufactured products include aircraft cabin seating, lighting systems, oxygen systems, food and beverage preparation and storage equipment, galley systems, and modular lavatory systems. The Company also provides cabin interior reconfiguration, program management and certification services. B/E Aerospace sells and supports its products through its own global direct sales and product support organization. For more information, visit the B/E Aerospace website at http://www.beaerospace.com.

Visit link:

JetBlue Launches New B/E Aerospace Seating Partnership

Southern California Stem Cell Therapy Clinic, TeleHealth, Now Offering Stem Cells for Knee Arthritis

Orange, CA (PRWEB) September 30, 2013

TeleHealth, the leading stem cell therapy clinic on the West Coast, is now offering multiple treatments with stem cells for knee arthritis. The stem cell treatments are very exciting as they present the possibility of repairing and regenerating arthritis damage in the knees. The treatments are offered by Board Certified stem cell doctors at the clinic in outpatient, low risk procedures that are often covered by insurance. Call (888) 828-4575 for more information and scheduling.

Over the past few years, increasing studies are showing the benefits of regenerative medicine treatments for knee arthritis. This includes a study out of the Hospital for Special Surgery last year showing effectiveness of platelet rich plasma therapy for knee arthritis. Treatment options at TeleHealth include both platelet rich plasma therapy (PRP therapy) along with bone marrow derived stem cell injection therapy or fat derived stem cell therapy.

Often, the treatments are combined to produce maximum knee arthritis benefit and allow patients to avoid surgery, reduce pain and dramatically increase functional ability. While knee replacement surgery has been shown to have a high success rate, the components are not meant to last forever and there can be complications with the surgery.

Therefore, it makes sense to try conservative treatment prior such as with the regenerative medicine options at TeleHealth. Especially considering the stem cell treatments are often covered by insurance.

TeleHealths main stem cell clinic is located in Orange, CA, convenient to major freeways and not far from San Diego, Los Angeles, Santa Ana and Inland Empire. The highly skilled stem cell doctors at the clinic are Board Certified and have years of experience treating musculoskeletal conditions with stem cell treatments including shoulder arthritis, rotator cuff tendonitis, Achilles tendonitis, tennis elbow, muscle tears and much more.

Call (888) 828-4575 for more information and scheduling.

Excerpt from:
Southern California Stem Cell Therapy Clinic, TeleHealth, Now Offering Stem Cells for Knee Arthritis

In Vitro Diagnostics: World Market Outlook 2013-2023

NEW YORK, Sept. 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

In Vitro Diagnostics: World Market Outlook 2013-2023 http://www.reportlinker.com/p0578540/In-Vitro-Diagnostics-World-Market-Outlook-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Report Details

In vitro diagnostic tests - your guide to trends and revenue prospects

What's the future of in vitro diagnostic (IVD) testing? Visiongain's updated report predicts those revenues to 2023. There you find the best places for sales growth, also understanding trends, technologies, and opportunities.

That study gives you revenue forecasts to 2023 at overall world market, submarket, and national level. See what's happening for those technologies, finding how you can gain.

Read on to explore that industry and see what its future market could be worth.

Forecasts 2013-2023 and other analyses to help you understand IVD potential

Besides revenue forecasting to 2023, our new work shows recent results, growth rates, and market shares. There you find original analysis. See technological developments too. You also get 52 tables, 40 charts, and two interviews. Many opportunities remain for those technologies and products. Now see how you can benefit your research, analyses, and decisions for IVD, also saving time. You hear what's happening there and see where the money lies. That way you reduce your risk of missing out. Finding data you need there just got easier. Try our new report.

The following sections show, then, how you benefit from our new investigation and analysis.

See original here:
In Vitro Diagnostics: World Market Outlook 2013-2023

ANSI Seeks Organizations to Take Part in International Standards Development Work on Microbiology

Previous | Printer-friendly

ANSI Seeks Organizations to Take Part in International Standards Development Work on Microbiology New York September 30, 2013

All U.S. stakeholder organizations in relevant fields and industries are strongly encouraged to get involved and help influence the development of standards in this important field. Participants will have the opportunity to assist with the development of international standards on food-related microbiology that will have a significant impact on both food and animal feeds.

ISO TC 34/SC 9 is responsible for the development of International Standards on topics connected to food-related microbiology. The subcommittee is actively at work on standards, including recently approved efforts to begin development of standards on microbiological methods for the detection of Salmonella and Bacillus cereus emetic toxin in food and animal feeds, among other projects. The U.S. TAG to TC 34/SC 9 is responsible for advising ANSI on voting positions relevant to proposed and in-development standards, and carrying out detailed discussions related to these documents.

As the U.S. member body to ISO, ANSI accredits U.S. TAGs to develop and transmit U.S. positions on ISO technical activities. ANSI currently serves as the U.S. TAG Administrator to TC 34/SC 9, with financial and technical support from the U.S. Food and Drug Administration (FDA).

Organizations interested in joining the TAG or seeking to obtain additional information about TC 34/SC 9, the U.S. TAG, and related activities should email tc34sc9@ansi.org. Additional information will be provided to all those who notify ANSI that they are interested in participating on the U.S. TAG.

Read this article:
ANSI Seeks Organizations to Take Part in International Standards Development Work on Microbiology

Vacuum dust: A previously unknown disease vector

Public release date: 30-Sep-2013 [ | E-mail | Share ]

Contact: Garth Hogan ghogan@asmusa.org 202-942-9389 American Society for Microbiology

The aerosolized dust created by vacuums contain bacteria and mold that "could lead to adverse effects in allergic people, infants, and people with compromised immunity," according to researchers at the University of Queensland and Laval University. Their findings are published ahead of print in Applied and Environmental Microbiology.

This finding is worrying as the study found resistance genes for five common antibiotics in the sampled bacteria along with the Clostridium botulinum toxin gene. This is of particular concern as, "The dust found indoors could act as a vehicle for infant botulism infection that can have severe consequences," including sudden infant death syndrome, according to previous studies.

"Even though no quantitative data are available for antibiotic resistance gene emission while vacuuming, the observed emission rates for bacteria might suggest that the genetic content of those bacterial cells, including antibiotic resistance genes, may contribute to indoor bioaerosol exposure," explain the researchers.

Researchers used a special clean air wind tunnel to measure vacuum emissions from 21 vacuums of varying quality and age. The clean air wind tunnel enabled them to eliminate other sources of particles and bacteria, says Knibbs. "That way, we could confidently attribute the things we measured purely to the vacuum cleaner."

The results were in accord with earlier studies which have shown human skin and hair to be important sources of bacteria in floor dust and indoor airwhich can be readily resuspended and inhaled, says report co-author, Caroline Duchaine.

Knibbs hopes that other studies will follow this one, raising the profile of potential indoor sources of culprits in unsolved medical cases. The investigators conclude their report, saying that vacuum cleaners are "underrepresented in indoor aerosol and bioaerosol assessment and should be considered, especially when assessing cases of allergy, asthma, or infectious diseases without known environmental reservoirs for the pathogenic or causative microbe."

###

A copy of the manuscript can be found online at http://bit.ly/1dMhUfw. Formal publication is scheduled for the October 2013 issue of Applied and Environmental Microbiology.

Read more here:
Vacuum dust: A previously unknown disease vector

Orthobiotiki Holdings Acquires Exclusive Distribution Rights of Celergen for Greece and Cyprus

ATHENS, Greece, Sept. 30, 2013 /PRNewswire/ --Orthobiotiki holdings, which was established in Athens in 2006 is dedicated to the specialty of Prevention, Anti-aging and Regenerative medicine. It has a state-of-the-art medical clinic in Athens, with 30 doctors of different specialties, treating patients from all over Europe. After years of research and trial, Orthobiotiki has decided to acquire the distribution rights of Celergen for Greece and Cyprus.

In recent years, Celergen, a Swiss-manufactured food supplement, has exponentially gained recognition worldwide and is featured in renowned and premier publications such as the Robb Report.

Prominent personalities, after experiencing the multi-faceted benefits of Celergen, have come forth and endorsed it. Miss Universe 1991, Lupita Jones, Magnum Group's founder, Dion R Friedland and the former President of the European Society of Anti-aging, Professor Michael Klentze, are just some of whom have taken and been benefitted from Celergen.

Consequently, Celergen is not only the choice supplement of the professional elite but has also become the preferred supplement that anti-aging doctors, plastic surgeons and functional doctors in the United States recommend to their patients.

Click here to view the Robb Report feature.

Dr. Uzzi Reiss, world famous Anti-aging specialist from Beverly Hills: "Celergen is a remarkable tool that can help improve our well-being on multiple levels. It is the Rolls Royce of supplements for the human body."

Dr. Bruce Lowell, Lowell Health and Longevity Center, Great Neck, New York: "Having seen first-hand proof of what Celergen can do, in both myself and my patients, I now know that something remarkable is definitely going on. I think Celergen marks the beginning of a new era in how we approach rejuvenating the human body."

Orthobiotiki holdings, interest in Celergen is a testament to just how grand a scale Celergen is being embraced at. Orthobiotiki, intends to promote Celergen in the Middle East and Europe as the preferred anti-aging supplement in its new venture into Preventive and Regenerative Healthcare".

For more information about Celergen please visit Orthobiotiki.com, celergenswiss.com (official European distributor) & celergenus.com (official US distributor).

Go here to read the rest:
Orthobiotiki Holdings Acquires Exclusive Distribution Rights of Celergen for Greece and Cyprus

Professor Arnold Caplan discusses mesenchymal stem cell therapy for multiple sclerosis – Video


Professor Arnold Caplan discusses mesenchymal stem cell therapy for multiple sclerosis
Professor Caplan is "The father of the mesenchymal stem cell (MSC)". In this clip, he describes a mouse experiment using human MSCs in a mouse model of MS. T...

By: http://www.cellmedicine.com

Read the rest here:

Professor Arnold Caplan discusses mesenchymal stem cell therapy for multiple sclerosis - Video

Insurance Covered Stem Cell Therapy in California at TeleHealth (888) 828-4575 – Video


Insurance Covered Stem Cell Therapy in California at TeleHealth (888) 828-4575
http://stemcelltherapyincalifornia.com Stem Cell Therapy procedures at TeleHealth are offered for a number of conditions and often covered by insurance. Thes...

By: USPainNetwork

Read more here:

Insurance Covered Stem Cell Therapy in California at TeleHealth (888) 828-4575 - Video

Stem cell therapy for burns, not aging, says FDA

MANILA, PhilippinesStem cell therapy should only apply to skin grafting for burn patients and not for anti-aging purposes, according to the Food and Drug Administration (FDA).

Up to now, there is no evidence that stem cell therapy has anti-aging effects, said FDA acting Director General Kenneth Hartigan-Go.

The FDA recognizes only hematopoietic (pertaining to the formation and development of blood cells) stem cell transplantation, corneal resurfacing with limbal stem cells and skin regeneration with epidermal stem cells as generally accepted standards of health care.

Asked if this meant anti-aging stem cell therapies would not be allowed in the Philippines, Go said: It means that if the health claim is for burn patients, requirements that need to be submittedlike clinical trial reportsare expected to be complete, whereas if the claim is for anti-aging, then the requirements may be more extensive and intensive considering that products for anti-aging claims are still controversial.

Facility accreditation

The FDA said it had been continuously collaborating with the Department of Healths Bureau of Health Facilities and Services (BHFS) in accrediting facilities that deal with human cells, tissues, and cellular and tissue-based products (HCT/Ps), laboratory and therapeutic activities or services.

As of Sept. 24, 51 facilities have applied for accreditation, and 11 of these have been inspected by the BHFS, the FDA said.

No automatic approval

Submission of an application, however, does not necessarily result in automatic approval.

The FDA guidelines require that all stem cell and cellular-based treatments offered in the country should first pass the agencys standards for safety, efficacy and quality.

Here is the original post:

Stem cell therapy for burns, not aging, says FDA

International Space Station- Expedition 37 Arrives at Station, Docks to Poisk – Video


International Space Station- Expedition 37 Arrives at Station, Docks to Poisk
A new trio of Expedition 37 residents has arrived at the International Space Station. Soyuz Commander Oleg Kotov and Flight Engineers Mike Hopkins and Sergey...

By: AussieNews1

Excerpt from:

International Space Station- Expedition 37 Arrives at Station, Docks to Poisk - Video

Space Station Live: Karen Nyberg’s Creative Skills and Technical Abilities – Video


Space Station Live: Karen Nyberg #39;s Creative Skills and Technical Abilities
Public Affairs Officer Nicole Cloutier interviews NASA astronaut Megan McArthur about her friendship with Expedition 37 Flight Engineer Karen Nyberg. She dis...

By: ReelNASA

Read the original:

Space Station Live: Karen Nyberg's Creative Skills and Technical Abilities - Video

Orbital’s Cygnus Spacecraft Successfully Berths with the International Space Station

DULLES, Va.--(BUSINESS WIRE)--

Orbital Sciences Corporation (ORB), one of the worlds leading space technology companies, today announced that its Cygnus cargo logistics spacecraft successfully completed its rendezvous and approach maneuvers with the International Space Station (ISS) and was grappled and berthed with the station by the Expedition 37 astronaut crew earlier this morning. After Cygnus was launched into orbit by Orbitals Antares rocket on Wednesday, September 18 from NASAs Wallops Flight Facility, it completed an extensive series of in-orbit tests and orbit-raising maneuvers demonstrating its readiness to operate in close proximity to the ISS. Final approach to the station began at about 3:00 a.m. (EDT) this morning, culminating with the stations robotic arm grappling the spacecraft at 7:00 a.m. when it was about 10 meters away. Cygnus was then guided to its berthing port on the nadir side of the ISS Harmony module where its installation was completed just before 8:45 a.m.

This entire COTS demonstration mission has been executed in textbook fashion by the joint NASA and Orbital teams, from Antares launch 10 days ago to Cygnus berthing at the station this morning, said Mr. David W. Thompson, Orbitals President and Chief Executive Officer. A tremendous amount of hard work has gone into this five-year effort from our launch vehicle and spacecraft teams, and we are all exceptionally proud of their accomplishments. We look forward to moving ahead with regularly scheduled ISS cargo delivery missions for NASA as early as the end of the year.

Orbital and NASA cooperatively developed the Cygnus cargo spacecraft under the Commercial Orbital Transportation Services (COTS) program that started in 2008. For the COTS demonstration mission, Cygnus carried a relatively light load of cargo to the ISS. The ISS crew will start unpacking the 700 kg of cargo and supplies tomorrow, which includes food, clothing and experimental equipment. In early October, they will begin filling the cargo module with up to 800 kg of disposal cargo prior to its departure. For future missions, Cygnus has a total cargo up-mass capacity of 2,000 kg in its standard configuration, expanding to 2,700 kg in its enhanced design for later missions. This first Cygnus will remain at the ISS for 30 days before departing for a destructive reentry over the Pacific Ocean in late October.

Following the successful completion of the COTS demonstration mission, Orbital will begin to carry out operational missions under the $1.9 billion Commercial Resupply Services (CRS) contract with NASA. The company will deliver approximately 20,000 kg of cargo to the ISS on eight more Antares/Cygnus missions through 2016. Each Cygnus cargo ship will carry crew food, clothing and other supplies; spare parts and equipment; and scientific experiments to the space station.

About Cygnus

Orbital developed the Cygnus cargo spacecraft as part of its COTS joint research and development initiative with NASA. Cygnus consists of a common Service Module (SM) and a Pressurized Cargo Module (PCM). The SM incorporates avionics, power, propulsion and communications systems already successfully flown aboard dozens of Orbitals LEOStar and GEOStar satellites. The PCM, designed and built by Thales Alenia Space under a subcontract from Orbital, is based on the Multi-Purpose Logistics Module (MPLM) previously used with the Space Shuttle. With a full load of cargo and fuel, the standard-configuration Cygnus weighs about 5,200 kg at launch and generates 3.5 kw of electrical power while in orbit. It is capable of extended-duration missions of a year or longer in space.

About Orbital

Orbital develops and manufactures small- and medium-class rockets and space systems for commercial, military and civil government customers. The companys primary products are satellites and launch vehicles, including low-Earth orbit, geosynchronous-Earth orbit and planetary spacecraft for communications, remote sensing, scientific and defense missions; human-rated space systems for Earth-orbit, lunar and other missions; ground- and air-launched rockets that deliver satellites into orbit; and missile defense systems that are used as interceptor and target vehicles. Orbital also provides satellite subsystems and space-related technical services to government agencies and laboratories. More information about Orbital can be found at http://www.orbital.com. Follow the company on Twitter @OrbitalSciences.

Read more here:

Orbital’s Cygnus Spacecraft Successfully Berths with the International Space Station

Cygnus cargo craft makes historic hookup with space station

International Space Station

Marcia Dunn The Associated Press

Sep. 29, 2013 at 11:42 AM ET

NASA via AP

A video view from NASA TV shows the Cygnus cargo spacecraft attached to the International Space Station's Canadian-built robotic arm during its capture and berthing on Sunday. At the time, both vehicles were travelling over the Indian Ocean.

CAPE CANAVERAL, Fla. NASA's newest delivery service made its first-ever shipment to the International Space Station on Sunday, another triumph for the booming commercial space arena that has its sights set on launching astronauts.

Orbital Sciences Corp.'s unmanned cargo ship, the Cygnus, pulled up at the orbiting lab with a half-ton of meals and special treats for the station astronauts who assisted in the high-flying feat.

With the smooth linkup, Orbital Sciences of Virginia became only the second company to accomplish such a far-flung shipment. The California-based SpaceX company took the lead last year.

Historic dayNASA officials along with White House representatives declared it a historic day.

"It was just a very, very impressive job ... I just couldn't be happier and more proud," said the NASA manager overseeing this commercial effort, Alan Lindenmoyer.

Go here to read the rest:

Cygnus cargo craft makes historic hookup with space station

NASA Hispanic Heritage Month Profile — Fernando Abilleira, Jet Propulsion Laboratory – Video


NASA Hispanic Heritage Month Profile -- Fernando Abilleira, Jet Propulsion Laboratory
Fernando Abilleira works at NASA #39;s Jet Propulsion Laboratory located in Pasadena, CA where he works as a Trajectory Analyst and Mission Design Engineer for t...

By: NASAtelevision

Read the original here:

NASA Hispanic Heritage Month Profile -- Fernando Abilleira, Jet Propulsion Laboratory - Video